← My Government dashboard

Government Watch

Dossier D.C. Cir. circuit opinion 26-jun-2026
A U.S. Court of Appeals ruling — binding precedent within that circuit, persuasive elsewhere.

Ardelyx, Inc. v. Robert F. Kennedy Jr.

Key claim: The U.S. Court of Appeals for the D.C. Circuit issued an opinion on June 26, 2026 in Ardelyx, Inc. v. Robert F. Kennedy Jr., a challenge involving HHS/FDA action affecting the company.

Abstract

U.S. Court of Appeals for the D.C. Circuit opinion decided 2026-06-26.

Why this matters

D.C. Circuit rulings on HHS/FDA drug-approval decisions shape the administrative-law boundaries within which the agency reviews and denies new drug applications, with downstream effects on patient access and manufacturer investment. The Ardelyx line of litigation has been closely watched as a test of judicial deference to FDA scientific judgments in the post-Loper Bright era.

Source

Link

Briefing card

Ardelyx, Inc. v. Robert F. Kennedy Jr.
Stage: circuit opinion · cadc · 26-jun-2026

The U.S. Court of Appeals for the D.C. Circuit issued an opinion on June 26, 2026 in Ardelyx, Inc. v. Robert F. Kennedy Jr., a challenge involving HHS/FDA action affecting the company.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: courtlistener:cadc:10880856

Ask about this finding

Replies are grounded in the abstract and metadata above. The model will quote directly when possible and say so if a question isn't covered.

Stages other doctrine resolution introduced proposed rule passed chamber executive action final rule enacted district opinion circuit opinion opinion

Subscribe: calendar of upcoming dates · deadlines feed · all new records

build build 392 · ea9c128-dirty · 2026-08-09